| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Nabriva Therapeutics plc [ NBRV ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 08/11/2022 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Share Options | $0.45 | 08/11/2022(1) | M | 93,400 | (1)(2) | 01/27/2032 | Ordinary Shares | 93,400(1) | $0 | 0(1) | D | ||||
| Restricted Stock Units | (3) | 08/11/2022(3) | M | 46,700 | (4) | (4) | Ordinary Shares | 46,700(3) | $0 | 0(3) | D | ||||
| Stock Appreciation Right | $0.45 | 08/11/2022(1) | M | 93,400 | (1)(2) | 01/27/2032 | Ordinary Shares | 93,400(1) | $0 | 93,400(1) | D | ||||
| Phantom Shares | (3) | 08/11/2022(3) | M | 46,700 | (4) | (4) | Ordinary Shares | 46,700(3) | $0 | 46,700(3) | D | ||||
| Explanation of Responses: |
| 1. The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the "2022 AGM") of Nabriva Therapeutics plc (the "Issuer"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right. |
| 2. Subject to the reporting person's continued employment with the Issuer, the cash-settled share appreciation right will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the cash-settled share appreciation right will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the cash-settled share appreciation right will vest on a monthly pro-rata basis over the remaining vesting period. |
| 3. The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( "Phantom Shares"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares. |
| 4. Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023. |
| /s/ J. Christopher Naftzger, by power of attorney | 08/15/2022 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||